69.27 3.04 (4.59%) | 02-13 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 91.7 ![]() |
1-year : | 102.14 ![]() |
Resists | First : | 78.51 ![]() |
Second : | 87.44 ![]() |
Pivot price | 70.82 ![]() |
|||
Supports | First : | 64.05 | Second : | 53.28 |
MAs | MA(5) : | 68.16 ![]() |
MA(20) : | 70.98 ![]() |
MA(100) : | 82.04 ![]() |
MA(250) : | 69.71 ![]() |
|
MACD | MACD : | -3.5 ![]() |
Signal : | -3.5 ![]() |
%K %D | K(14,3) : | 20.5 ![]() |
D(3) : | 17.8 ![]() |
RSI | RSI(14): 40 ![]() |
|||
52-week | High : | 103.8 | Low : | 45.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRCT ] has closed above bottom band by 33.9%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 69.44 - 69.69 | 69.69 - 69.9 |
Low: | 64.51 - 64.83 | 64.83 - 65.08 |
Close: | 68.78 - 69.28 | 69.28 - 69.69 |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Thu, 13 Feb 2025
Mid-Cap Miracles: Why Investors Are Eyeing Procept BioRobotics - MotoPaddock
Thu, 13 Feb 2025
Procept BioRobotics Corp. (PRCT): Among the Best Mid-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Wed, 12 Feb 2025
Legato Capital Management LLC Has $2.51 Million Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) - MarketBeat
Mon, 10 Feb 2025
abrdn plc Has $5.69 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT) - MarketBeat
Fri, 07 Feb 2025
PROCEPT BioRobotics® to Report Fourth Quarter 2024 - GlobeNewswire
Fri, 07 Feb 2025
PROCEPT BioRobotics (PRCT) Earnings Alert: Strategic Healthcare Conference Lineup Revealed - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 54 (M) |
Shares Float | 50 (M) |
Held by Insiders | 4.5 (%) |
Held by Institutions | 89.3 (%) |
Shares Short | 7,070 (K) |
Shares Short P.Month | 6,180 (K) |
EPS | -1.96 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.63 |
Profit Margin | -50.1 % |
Operating Margin | -38.5 % |
Return on Assets (ttm) | -16.8 % |
Return on Equity (ttm) | -37.1 % |
Qtrly Rev. Growth | 66.3 % |
Gross Profit (p.s.) | 2.11 |
Sales Per Share | 3.69 |
EBITDA (p.s.) | -1.88 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -92 (M) |
Levered Free Cash Flow | -83 (M) |
PE Ratio | -35.53 |
PEG Ratio | 0 |
Price to Book value | 14.96 |
Price to Sales | 18.75 |
Price to Cash Flow | -40.92 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |